



Syprine[®] (trientine) – First-time generic

- On February 9, 2018, [Teva Pharmaceuticals](#) launched an [AB-rated](#) generic version of Valeant's [Syprine \(trientine\)](#) 250 mg capsules.
- Syprine is approved for the treatment of patients with Wilson's disease who are intolerant of penicillamine ([Cuprimine[®] capsules](#), [Depen[®] tablets](#)).
 - Syprine is not recommended in cystinuria or rheumatoid arthritis.
 - Syprine is not indicated for treatment of biliary cirrhosis.
- Syprine had annual sales of approximately \$155 million in the U.S. according to IMS data as of November 2017.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.